Format

Send to

Choose Destination
Crit Rev Oncol Hematol. 2011 Jul;79(1):17-23. doi: 10.1016/j.critrevonc.2010.07.004. Epub 2010 Aug 2.

Epithelial ovarian cancer: focus on targeted therapy.

Author information

1
Second Department of Internal Medicine, Propaedeutic Oncology Section, University of Athens, "Attikon" University Hospital, Haidari, Greece. kpliarch@otenet.gr

Abstract

Ovarian cancer remains the leading cause of gynecological cancer-related mortality in the Western World despite the advances in surgical techniques and chemotherapy regimens over the past three decades. Although response rates and complete responses in advanced disease are >80% and 40-60%, respectively, after first-line treatment with carboplatin and paclitaxel, most of the patients will eventually relapse with a median progression-free survival of 18 months. Currently, research efforts have improved our understanding on the molecular biology of ovarian cancer and novel targeted treatment strategies are likely to contribute to the management of the disease and give the chance to an individualized therapeutic approach.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center